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Abstract
Background: Although there is increasing evidence for a relationship between symptomatic Zika virus (ZIKV)
maternal infection, and microcephaly, a firm causal relation has yet to be established by epidemiologic studies.
Studies also need to be conducted in recently infected settings. Our objectives are to assess the frequency of ZIKV
infection during pregnancy in Honduras and the association of microcephaly with ZIKV infection.
Methods/Design: We will perform a prospective study enrolling pregnant women at their first antenatal visit and
following them up until delivery. At the time of enrollment, women will be interviewed to collect socio-demographic
data, data needed to locate them for potential additional follow-up, and data about ZIKV symptoms during pregnancy.
We will also collect maternal blood as soon as possible after enrollment. A probable maternal ZIKV infection will be
defined as positive for maternal ZIKV IgM. A confirmed maternal ZIKV infection will be defined as positive for ZIKV IgM
confirmed by plaque reduction neutralization test. Microcephaly at birth will be defined as an occipito-frontal
circumference <2SD for sex and gestational age. Our objective is to enroll 2000 pregnant women. In a first step,
we will follow a case cohort design and only analyze blood samples for cases and a sub-cohort of 200 women
randomly selected. Blood samples for the entire population will be analyzed at a later stage if funds are available.
Discussion: This protocol was designed to be implemented with minimal resources. It allows a cohort to be
built, which could be a foundation for future in-depth and follow-up studies.
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Plain english summary
There is increasing evidence that mothers infected with
Zika virus (ZIKV) during pregnancy could have a baby
with microcephaly (a small head), but doubts persist and
the magnitude of this risk is still uncertain. Studies also
need to be conducted in countries where ZIKV just ar-
rived. Our objectives are to assess the frequency of ZIKV
infection during pregnancy in Honduras and the associ-
ation of microcephaly with ZIKV infection.
We will perform a study enrolling pregnant women at
their first antenatal visit and following them up until de-
livery of their baby. At the time of first antenatal care
visit, women will be asked questions about themselves,
such as their level of education; about the best way to lo-
cate them for potential additional follow-up; and about
ZIKV symptoms during pregnancy. We will also collect
maternal blood as soon as possible after enrollment. We
will ask the hospital where they will deliver to measure
the head of the baby. Our objective is to enroll 2000
pregnant women. We will analyze the blood samples of
the mothers of babies with microcephaly and of some
of the mothers of normal babies. Blood samples of
everybody will be analyzed at a later stage if funds
are available.
Background
Beginning in October 2015, Brazil reported a cluster of
cases of microcephaly in newborns from the Northeast
Region [1]. Additionally, French Polynesia reported an in-
creased number of central nervous system malformations
* Correspondence: pbuekens@tulane.edu
1School of Public Health and Tropical Medicine, Tulane University, 1440 Canal
Street, Ste. 2430, New Orleans, LA 70112, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Buekens et al. Reproductive Health  (2016) 13:82 
DOI 10.1186/s12978-016-0200-6
in neonates from March 2014 to May 2015 [1]. Although
there is increasing evidence for a relationship with symp-
tomatic Zika virus (ZIKV) maternal infection, a firm
causal relation has yet to be established [2, 3]. ZIKV was
detected in the amniotic fluid [4] and fetal brain tissue [5]
of fetuses diagnosed with microcephaly antenatally and
confirmed after birth. It has been also shown in in vitro
experiments that ZIKV infects human cortical neural cell
progenitors and limits their growth [6]. Data from French
Polynesia suggest that first-trimester infections are linked
to the highest risk of fetal complications [7]. A recently
published study conducted in Rio de Janeiro, Brazil, re-
ported that, within a cohort of pregnant women who had
clinically symptomatic, laboratory-confirmed ZIKV infec-
tion during pregnancy, 29 % had fetal cranial-brain anom-
alies identified by ultrasound [3]. Women without ZIKV
infection had no cases diagnosed antenatally, but the sam-
ple size was small. One of the difficulties of studies where
cases are identified at birth is that it is often impossible to
determine if a woman was infected by ZIKV earlier in
pregnancy. The virus can be identified by RT-PCR only
during a few days after infection, and IgM can only be
identified for a few weeks after infection [8]. Another chal-
lenge is the serological cross-reactivity between ZIKV and
other related viruses (e.g., dengue) [8]. A review of the evi-
dence supporting a causal relationship between ZIKV and
microcephaly noted that the “consistent findings by ≥2
high-quality epidemiologic studies” criterion was only par-
tially met [9].
In response to this situation, the Emergency Commit-
tee convened by the World Health Organization (WHO)
on March 8th recommended that research should be in-
tensified, with particular attention to studies that are
conducted in more recently infected settings [2]. In
Honduras, 19,693 suspected cases of ZIKV infection
have been reported during the first nineteen weeks of
2016 [10]. An earlier study performed in Tegucigalpa,
Honduras, showed that the frequency of dengue started
increasing around June 1st and was at its maximum in
July [11]. We are assuming that ZIKV infection will fol-
low a similar pattern.
We will conduct a prospective study in Honduras aim-
ing to assess the frequency of ZIKV infection during
pregnancy, and the association of ZIKV infection with
microcephaly. The Specific Aims are the following:
Specific aim 1
To measure the frequency of ZIKV infection in pregnancy.
Specific aim 2
To measure the association between symptomatic and
asymptomatic maternal ZIKV infection during preg-
nancy and microcephaly at birth.
Hypothesis
Mothers who were infected with ZIKV during pregnancy
have an increased risk of microcephaly.
Methods/Design
Overview of study design
We will perform a prospective study enrolling pregnant
women at their first antenatal visit and following them
up until delivery. We will enroll pregnant women at-
tending the Alonso Suazo Health Center (Tegucigalpa,
Honduras) at their first antenatal visit. At the time of
enrollment, women will be interviewed to collect socio-
demographic data, data needed to locate them for po-
tential additional follow-up (e.g., household location,
municipality of residence, cell phone number), and data
about ZIKV symptoms during pregnancy. We will also
collect maternal blood as soon as possible after enroll-
ment. A probable maternal ZIKV infection will be de-
fined as positive for maternal ZIKV IgM [2]. Head
circumference at birth and gestational age estimated by
last menstrual period and by Capurro scores [12] (or
equivalent) will be used to diagnose microcephaly.
Microcephaly at birth will be defined as an occipito-
frontal circumference <2SD for sex and gestational age,
using the INTERGROWTH-21st charts [13, 14]. In a
first step, we will follow a case cohort design and only
analyze blood samples for cases and a sample of the en-
tire population (sub-cohort) [15]. Blood samples for the
entire population will be analyzed at a later stage if
funds are available.
Settings
We will enroll women attending the Alonso Suazo
Health Center (Tegucigalpa, Honduras), which had 7105
first antenatal visits in the last two years.
Participants
Inclusion criteria
We will require written informed consent from the
mother if she is 18 years or older. For mothers <18 years
old, we will require written assent and written consent
from at least one parent or guardian.
Variables
Exposure and main outcome
– ZIKV infection - A suspected ZIKV infection during
pregnancy will be defined as rash and/or fever and
at least one of following signs or symptoms:
arthralgia, arthritis, conjunctivitis (non-purulent/
hyperemic). A probable maternal ZIKV infection
will be defined as positive for maternal ZIKV IgM. A
confirmed maternal ZIKV infection will be defined
as positive for ZIKV IgM confirmed by plaque
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reduction neutralization test (PRNT). These
definitions are based on interim case definitions
proposed by WHO as of February 12, 2016, and
might be updated in the future [1]. Date (day,
month, year) of suspected, probable, and confirmed
diagnosis will be registered.
– Head circumference (cm) - A confirmed case of
microcephaly will be defined as an occipito-frontal
circumference <2SD for sex and gestational age,
using the INTERGROWTH-21st charts [13, 14].
Other birth outcomes
– A live birth is a baby born with any sign of life,
irrespective of gestational age [16].
– A stillbirth is a baby born without any sign of life
and birthweight of ≥500 g; or, if missing, ≥22
completed weeks of gestation; or, if missing, body
length ≥25 cm [16].
– Gestational age (completed weeks), based on the
Last Menstrual Period (LMP) or a clinical estimate.
The clinical estimate will be based on the Capurro
Score (or equivalent) [12]. This score is the standard
method to evaluate gestational age by physical
examination of an infant at birth, widely used in
Latin America. The clinical estimate will be used if
the discrepancy between the LMP-based estimate
and the clinical estimate is greater than 10 days; a
preterm birth is <37 weeks; a very preterm birth is
<32 weeks.
– Multiple pregnancy.
– Birthweight (grams); a low birthweight baby weighs
<2500 g; a very low birthweight baby weighs <1500 g.
– Body length (cm).
Maternal characteristics
– Maternal age (years); parity (including current birth).
– Reproductive history (year of occurrence): previous
pregnancies, abortions, stillbirths, live births, infants’
or children’s death.
– Educational level (completed years).
– Household location and municipality.
Data sources: clinical data, socio-demographic data, and
geographical data
Clinical data and socio-demographic data
Data about the mother will be collected by interview-
ing the mother and from the medical histories. Data
about the newborn will be collected from medical
histories. An insertion tape (Seca 212 or equivalent)
will be recommended for measuring head circumfer-
ence and an infantometer (Seca 416 or equivalent) for
length. Study personnel will be trained in abstracting
medical histories.
Geographical data
Street addresses will often be unreliable in the areas
where participating women live; thus, detailed informa-
tion will be collected at enrollment:
– Household location (addresses will be registered if
available).
– Municipality of residence. Interviewers will have a
list of municipalities available during the interview
and will verify that the name of the municipality is
valid.
– Cell phone number of the participants.
Study personnel familiar with the area will use the in-
formation provided by the mother to geocode the house-
hold location using Google Earth. In a previous study,
our staff were able to locate the households in the field
in more than 90 % of the cases and used Google Earth
to document the locations. If the probable household lo-
cation is within the municipality of residence provided
by the mother, the municipality will be confirmed as




A minimum of 5 mL of venous maternal blood and no
more than 10 mL will be collected as soon as possible
after enrollment. We estimate from our previous studies
that >99 % of the maternal samples will be usable.
Storage of biological samples
Consent forms will include an opt-out provision that
otherwise allows participating study institutions to store
blood specimens for up to ten years for confirmatory
studies (including diagnosis of co-infections) and for po-
tential genetic studies linked to mother-to-child trans-
mission of ZIKV. In our previous studies, >99 % of the
participating women have accepted the storage.
Blood samples will be stored in part on filter paper
kept in plastic bags with desiccant at 4 °C until use, and
additional samples (e.g., serum or plasma) will be frozen
at or below −20 °C until use. Freezer-safe barcode labels
(Brady, Milwaukee, WI, or equivalent) will be pasted on
each of the biological samples and will be scanned to
document the location of the samples. Temperatures of
freezers and refrigerators will be monitored by digital
temperature data loggers (SM320, Dickson, Addison, IL,
or equivalent). The Data Center will manage the barcode
and temperature data.
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Laboratory procedures
Investigators and staff performing the laboratory proce-
dures will be blinded for the presence of microcephaly.
We will measure ZIKV IgM on maternal blood, using
tests and procedures recommended by the CDC [8].
Stored specimens will also allow for future serological
testing, molecular analyses, and testing for insecticides,
including larvicides.
Data management
Data management will be similar to the plan we have
used in previously funded studies and will be coordi-
nated by the Institute for Clinical Effectiveness and
Health Policy (Instituto de Efectividad Clínica y Sanitaria
[IECS], Buenos Aires, Argentina). Data will be collected
on paper forms designed specifically for the study. For
each participating woman, a study number (alpha-nu-
meric, with check digit) will be assigned. A set of labels
with each number will be designed to be pasted on the
data forms of the mother and her newborn, and a
freezer-safe barcode label (Brady, Milwaukee, WI, or
equivalent) will be pasted on each of the biological sam-
ples. An inclusion form will be used to collect data dur-
ing participants’ enrollment. Names and other personal
identifiers will be recorded in the inclusion form header,
which will be stripped from the main body containing
data. Each part will be identified with a study label num-
ber. The inclusion form body will be sent to the local
data center for data entry. This system ensures that per-
sonal identifiers will not be taken from the study site
and will be kept securely by the site coordinator.
The data forms will be entered in OpenClinica, a se-
cure web data management system (v 3.1.4.1or higher),
or REDCap [17] which is an open source software for
clinical research studies using distributed data entry.
Additionally, digital pictures (with date and time) or
scans of each data form will be taken and will be regu-
larly sent (encrypted) to IECS. This system will allow for
a digital backup of all study data forms, as well as a par-
allel second data entry of 10 % of the forms at IECS, to
detect systematic errors at data entry.
In addition, the Data Center will manage the informa-
tion from the freezers’ and refrigerators’ temperature
data loggers, preparing graphs and detecting values out
of expected range. The Data Center will also manage the
stock information from the scanned biological samples
barcodes.
Monitoring will be done through weekly on-site visits
to the Alonso Suazo Health Center by the site coordin-
ator, who will complete weekly reports that will be sub-
mitted to the Data Center. Data Center staff will
conduct weekly monitoring calls with the site coordin-
ator to discuss site reports and will produce weekly sum-
mary reports, which will be submitted to the Principal
Investigator and the study coordinating center. For qual-
ity assurance, the Principal Investigator and Data Center
staff will perform at least one site visit. During the site
visits, source data and biological samples verification will
be performed in 10 % of cases and 10 % of controls. All
storage and laboratory procedures will be audited as
well.
Sample size
Our objective is to enroll 2000 pregnant women. A sub-
cohort of 200 women will be randomly selected.
Specific aim 1
The sub-cohort of 200 women will allow us to measure
a seroprevalence of 5 % with a 95 % confidence interval
of + − 3 %.
Specific aim 2
Assuming a 2 % frequency of microcephaly, we estimate
that 40 cases and a sub-cohort of 200 women will give
us 80 % power (0.05 alpha level) to detect an odds ratio
(OR) of 5 for the association between ZIKV infection
and microcephaly, if the prevalence of ZIKV infection is
5 % (Fig. 1). A higher prevalence of ZIKV infection
would increase the power.
Plan for data analysis
We will initially follow a case-cohort design. A sub-cohort
of 200 women will be randomly selected. We will compute
the frequency of ZIKV infection among the sub-cohort
(Specific Aim 1). Blood samples for the entire population
will be analyzed at a later stage if funds are available, and
frequency of ZIKV infection will be computed accord-
ingly. Logistic regression analysis will be used to estimate
crude and adjusted ORs and corresponding 95 % Confi-
dence Intervals (CIs) for the association between maternal
ZIKV virus infection and microcephaly (Specific Aim 2).
Potential confounders (e.g., municipality of residence, edu-
cational level) will be entered in the model. If the OR esti-
mate changes by 10 % or more after controlling for a
given variable, subsequent OR estimates will be adjusted
for that variable. We will perform sub-group analysis by
presence or absence of ZIKV symptoms (“Suspected
ZIKV”) at or before the first antenatal visit.
We will use STATA v12.0 or higher (StataCorp, Col-
lege Station, TX) for data analysis.
Study organization
Our steering committee includes the Principal Investiga-
tor, the Co-Principal Investigator from Honduras, and one
Co-Investigator from the Data Center. A local coordinat-
ing center will be established in Honduras. The IECS in
Buenos Aires, Argentina, will act as the study Data Center,
thereby providing a specific data monitoring system,
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assuring maintenance of high quality databases, supervis-
ing all data collection procedures, and arranging for the
most efficient transfer of study data.
Timeline and tasks
The study will include two months of preparatory activ-
ities, an estimated 12 months of enrollment, and
10 months for follow up, laboratory procedures, data
analysis, and reporting.
During the preparatory phase (I), we will develop (in
Spanish) the Manual of Operations, the Data Manage-
ment System, and data collection forms and post them
on our password-protected website. We will also train
the data collection personnel. During the enrollment
phase (II), we will enroll women and perform lab ana-
lyses, which will continue during the last phase of the
study (Phase III). Data collection at birth will continue
during Phase III. Data analysis will be conducted during
Phase III.
Discussion
This protocol was designed to be implemented with
minimal resources, with blood samples collected as early
as possible during pregnancy being stored for future
analyses. We are following a modular approach, with the
current protocol being the foundation module on which
additional future in-depth studies could be added. Po-
tential future modules could include more in-depth data
collection during pregnancy and follow-up studies of
ZIKV infected mothers and their children.
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